SCHEMBL6719403

SCHEMBL6719403

Cc1cccc(NC(=O)C(c2ccccc2)N(S)C(=O)Nc2ccccc2F)c1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.46
GAA P10253 2/20 0.46
MEN1 O00255 5/20 0.45
KMT2A Q03164 5/20 0.45
POLB P06746 1/20 0.45
RAB9A P51151 2/20 0.42
KDM4E B2RXH2 1/20 0.41
MAPT P10636 2/20 0.41
NPC1 O15118 1/20 0.41
NFKB1 P19838 1/20 0.41
NFKB2 Q00653 1/20 0.41
RELA Q04206 1/20 0.41
TP53 P04637 1/20 0.40
LMNA P02545 2/20 0.40
CA12 O43570 1/20 0.40
CA1 P00915 1/20 0.40
CA2 P00918 1/20 0.40
CA9 Q16790 1/20 0.40
ALOX12 P18054 1/20 0.40
HTT P42858 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6715845 0.89 GAA (0.51) ALDH1A1GAAMEN1KMT2APOLB
SCHEMBL6715735 0.86 TRPV1 (0.48) ALDH1A1GAAMEN1KMT2APOLB
SCHEMBL6727005 0.85 MAPT (0.50) ALDH1A1MEN1KMT2ARAB9AKDM4E
SCHEMBL6717589 0.84 MEN1 (0.48) ALDH1A1MEN1KMT2APOLBRAB9A
SCHEMBL6715571 0.80 KDM4E (0.50) ALDH1A1MEN1KMT2APOLBRAB9A
SCHEMBL6723214 0.79 ALDH1A1 (0.52) ALDH1A1GAAMEN1KMT2APOLB
SCHEMBL6719400 0.77 ULK1 (0.51) ALDH1A1GAAMEN1KMT2APOLB
SCHEMBL6715691 0.77 MAPT (0.54) ALDH1A1MEN1KMT2APOLBRAB9A
SCHEMBL6716963 0.75 RAB9A (0.59) ALDH1A1GAAMEN1KMT2APOLB
SCHEMBL6716912 0.75 KDM4E (0.57) ALDH1A1GAAMEN1KMT2APOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040152741-A1 Arylglycine derivatives and their use as glycine transport inhibitors NPS ALLELIX CORPORATION (CA) 2004-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040152741-A1 Arylglycine derivatives and their use as glycine transport inhibitors SLC1A2, SLC1A1, SLC7A11 ALDH1A1 575/4885GAA 168/4885MEN1 2822/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.